What is BTAI (BTAI) stock price today?

BTAI (BTAI) is currently trading at $0.07, up 0% today.

What is BTAI P/E ratio?

BTAI's P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is BTAI return on equity (ROE)?

BTAI's return on equity (ROE) is 69.92%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is BTAI's market cap?

BTAI has a market capitalization of $2.28M.

NASDAQ · Biotechnology

BTAI (BTAI) Stock

$0.07 +0.00% NASDAQ: BTAI Healthcare

Valuation

Metric	Value
Price	$0.07
Market Cap	$2.28M
P/E Ratio	-0.02
P/B Ratio	-0.01
P/S Ratio	4.45
EPS (TTM)	$0.00
52-Week High	$4.29
52-Week Low	$0.07
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	69.92%
ROA	-246.05%
ROCE	41.19%
Gross Margin	-5000.00%
Operating Margin	-5000.00%
Net Margin	-110.79%
Debt/Equity	-0.90
Current Ratio	0.83

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$1.0M	$2.0M	$1.0M
Operating Profit	$-107.0M	$-160.0M	$-172.0M	$-67.0M	$-50.0M
Net Profit	$-107.0M	$-166.0M	$-179.0M	$-60.0M	$-70.0M
EPS	$-64.87	$-94.67	$-98.35	$-23.51	$-5.73
Op Margin	—	-42572.0%	-12448.0%	-2967.6%	-7829.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$239.0M	$206.0M	$74.0M	$38.0M	$45.0M
Total Liabilities	$18.0M	$129.0M	$130.0M	$131.0M	$140.0M
Cash	$233.0M	$194.0M	$65.0M	$30.0M	$28.0M
Borrowings	$1.0M	$94.0M	$101.0M	$103.0M	$110.0M

Latest News

What Makes BioXcel Therapeutics (BTAI) a New Buy Stock Zacks · Jun 2, 2026 BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting GlobeNewswire · May 28, 2026 BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates Zacks · May 15, 2026 BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026 CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates Zacks · May 14, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-82.0M	$-135.0M	$-155.0M	$-72.0M	$-58.0M
Investing Cash Flow	$-1.0M	$0	$0	$0	$0
Financing Cash Flow	$1.0M	$-3.0M	$-1.0M	$-1.0M	$0
Net Cash Flow	$20.0M	$-39.0M	$-129.0M	$-35.0M	$-1.0M
Free Cash Flow	$-83.0M	$-135.0M	$-155.0M	$-72.0M	$-58.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-1.78
FCF Yield	-1540.72%
Quick Ratio	0.21
Interest Coverage	-2.59
Return 1Y	-51.05%
Return 3Y	-99.44%
Return 5Y	-99.79%

Ownership

Insiders Held3.65%

Institutions Held18.72%

Institutions Float Held19.43%

Institutional Holder	Shares	Report Date
Millennium Management Llc	1,936,760	2026-03-31
Armistice Capital, LLC	1,910,076	2026-03-31
Oaktree Capital Management LP	241,188	2026-03-31
Geode Capital Management, LLC	230,168	2026-03-31
Vanguard Capital Management LLC	207,339	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ANVSAnnovis Bio, Inc.	$1.21	+3.42%	-0.67	$51.48M	0.00%
BCAB	$1.74	+0.00%	-0.12	$2.88M	0.00%
CELUCelularity Inc.	$1.56	+6.85%	-0.51	$45.16M	0.00%
EVAXEvaxion Biotech A/S	$3.05	+0.66%	-1.99	$19.27M	0.00%
GBIOGeneration Bio Co.	$5.34	+0.00%	-0.87	$35.98M	0.00%

About BTAI

BTAI is led by CEO Vimal D. Mehta, employs 37 people, headquartered in US, publicly traded since 2018.

BTAI stock trades at $0.07 with a market capitalization of $2.28M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of -0.01, price-to-sales of 4.45. Over the past 52 weeks the stock has ranged between $0.07 and $4.29, and currently trades 98.4% below its 52-week high.

On profitability, BTAI generates a return on equity (ROE) of 69.92% — well above the market average, a sign of a high-quality business, return on capital employed of 41.19%, an operating margin of -5000.00%, a net profit margin of -110.79%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides